title: I-SPY2 trial yields first results on combination therapy for triple-negative breast cancer.
authors.forename: Carrie
authors.initials: C
authors.lastname: Printz
mesh_terms: D018943:Anthracyclines / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols; D001562:Benzimidazoles / Q000008:administration & dosage; D016190:Carboplatin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D017239:Paclitaxel / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D064726:Triple Negative Breast Neoplasms / Q000188:drug therapy* / Q000601:surgery
chemical_list: D018943:Anthracyclines; D000972:Antineoplastic Agents, Phytogenic; D001562:Benzimidazoles; C521013:veliparib; D016190:Carboplatin; D017239:Paclitaxel